ClinicalTrials.gg
CompletedNCT01101321Updated Nov 18, 2015Results posted

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

A Phase 1 interventional study of Reformulated OXY (Totowa) (oxycodone HCl) and Reformulated OXY (Wilson) (oxycodone HCl) in Healthy, sponsored by Purdue Pharma LP. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-18.

Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) manufactured at the Totowa, NJ facility relative to the formulation (80 mg) manufactured at the Wilson, NC facility in the fasted state.

Read the detailed description

Oxycodone hydrochloride (oxycodone) is a semi-synthetic opioid analgesic that is effective in the relief of moderate to severe malignant and non-malignant pain.

02

Conditions studied

  • Healthy

Keywords

  • Healthy subjects
  • Opioid
  • Healthy volunteers
03

In context

Lead sponsor

Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.

First submitted before Purdue Pharma LP became part of Knoa Pharma.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18 to 50, inclusive.
  • Body weight ranging from 50 to 100 kg and a ≥18 and ≤34 (kg/m2).
  • Healthy and free of significant abnormal findings as determined by medical history, physical examination, vital signs, and .
  • Females of must be using an adequate and reliable method of .

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or lactating.
  • Any history of or current drug or alcohol abuse for 5 years.
  • History of or any current conditions that might interfere with drug absorption, distribution, metabolism or excretion.
  • Use of an opioid-containing medication in the past 30 days.
  • History of known sensitivity to oxycodone, naltrexone, or related compounds.
  • Any history of frequent nausea or emesis regardless of etiology.
  • Any history of seizures or head trauma with current sequelae.
  • Participation in a clinical drug study during the 30 days preceding the initial dose in this study.
  • Any significant illness during the 30 days preceding the initial dose in this study.
  • Use of any medication including thyroid hormone replacement therapy (hormonal is allowed), vitamins, herbal, and/or mineral supplements, during the 7 days preceding the initial dose.
  • Refusal to abstain from food for 4 hours following administration of the study drugs and to abstain from caffeine or xanthine entirely during each confinement.
  • Consumption of alcoholic beverages within forty-eight (48) hours of initial study drug administration (Day 1) or anytime following initial study drug administration.
  • History of smoking or use of nicotine products within 45 days of study drug administration or a positive urine cotinine test.
  • Blood or blood products donated within 30 days prior to administration of the study drugs or anytime during the study, except as required by this protocol.
  • Positive results for urine drug screen or alcohol screen at Check-in of each period, and , HBsAb (unless immunized), anti-.
  • Positive Naloxone HCl challenge test.
  • Presence of Gilbert's Syndrome or any known hepatobiliary abnormalities.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Reformulated OXY 80 mg (Totowa)

    Reformulated OXY 80 mg (Totowa) x 1 dose

    Drug: Reformulated OXY (Totowa) (oxycodone HCl)

  • Active comparator
    Reformulated OXY 80 mg (Wilson)

    Reformulated OXY 80 mg (Wilson) x 1 dose

    Drug: Reformulated OXY (Wilson) (oxycodone HCl)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Plasma Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 72-hour period

  2. AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 72-hour period

  3. AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 72-hour period

07

Results

Posted May 12, 2010

Participant flow

23-Jun-2008 (first Informed Consent Form signed) to 19-Aug-2008 (last subject last visit), at 1 site in the US (Honolulu, HI).

Period 1
Participant flow — Period 1
MilestoneReformulated OXY (Totowa) (Test) FirstReformulated OXY (Wilson) (Reference) First
Started3028
Completed2624
Not completed44
Withdrew: Withdrawal by subject11
Withdrew: Adverse event33
Period 2
Participant flow — Period 2
MilestoneReformulated OXY (Totowa) (Test) FirstReformulated OXY (Wilson) (Reference) First
Started2624
Completed2624
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Plasma Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 72-hour period
Reported as:
Mean · ng/mL
Cmax - Maximum Observed Plasma Concentration
ng/mLReformulated OXY (Totowa) (Test)Reformulated OXY (Wilson) (Reference)
Cmax - Maximum Observed Plasma Concentration78.4 ± 20.878.2 ± 20.2
Statistical analysis
  • Reformulated OXY (Totowa) (Test) vs Reformulated OXY (Wilson) (Reference) · ANOVA · Geometric test/ref ratio x 100: 100 · 90% CI 96.14 to 104.96Bioequivalence is established when 90% Confidence Interval falls within 80%-125%.
PrimaryAUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 72-hour period
Reported as:
Mean · ng*h/mL
AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
ng*h/mLReformulated OXY (Totowa) (Test)Reformulated OXY (Wilson) (Reference)
AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)846 ± 223850 ± 191
Statistical analysis
  • Reformulated OXY (Totowa) (Test) vs Reformulated OXY (Wilson) (Reference) · ANOVA · Geometric test/ref ratio x 100: 98.5 · 90% CI 95.44 to 101.73Bioequivalence is established when 90% Confidence Interval falls within 80%-125%.
PrimaryAUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 72-hour period
Reported as:
Mean · ng*h/mL
AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
ng*h/mLReformulated OXY (Totowa) (Test)Reformulated OXY (Wilson) (Reference)
AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration843 ± 223848 ± 191
Statistical analysis
  • Reformulated OXY (Totowa) (Test) vs Reformulated OXY (Wilson) (Reference) · ANOVA · Geometric test/ref ratio x 100: 98.5 · 90% CI 95.42 to 101.70Bioequivalence is established when 90% Confidence Interval falls within 80%-125%.

Adverse events

Collected over Ongoing AEs-followed until resolution/30 days after last dose;AEs reported during 7 days following last dose were recorded & followed until resolution or up to 30 days after last dose. All SAEs were followed until resolution or event/sequelae stabilized.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reformulated OXY (Totowa) (Test)—0/54 (0%)29/54 (53.7%)
Reformulated OXY (Wilson) (Reference)—0/54 (0%)22/54 (40.7%)
Most frequent other events
Most frequent other events
EventReformulated OXY (Totowa) (Test)Reformulated OXY (Wilson) (Reference)
HeadacheNervous system disorders13/548/54
NauseaGastrointestinal disorders11/547/54
SomnolenceNervous system disorders11/545/54
VomitingGastrointestinal disorders8/548/54
DizzinessNervous system disorders8/546/54
Abdominal PainGastrointestinal disorders4/546/54
FatigueGeneral disorders3/544/54
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/544/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomized Safety Population
Mean30 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Safety Population
Female22
Male36
08

Study locations

1 site
  • Covance Clinical Research Unit Honolulu
    Honolulu, Hawaii 96813, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Aug 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 9, 2010
Start
Jun 2008
Primary completionActual
Aug 2008
CompletionActual
Nov 2008
Results first posted
May 12, 2010
Last update
Nov 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01101321
Lead sponsor
Purdue Pharma LP
Responsible party
Sponsor
First posted
Apr 9, 2010
Start date
Jun 2008
Primary completion
Aug 2008
Completion
Nov 2008
Results posted
May 12, 2010
Last update
Nov 18, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion